Clinical Trial

Clinical Performance Evaluation of MagIA IVD-MD Multiplex Testing (HIV/HBV/HCV/Syphilis)

Study acronym: MAGICS IBCS
Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated February 2, 2026 (before its estimated April 2026 completion). Its status may not reflect the trial's current state.
Summary
Performance study to evaluate the clinical performance of the In-Vitro Diagnostics Medical Device MagIA H3S (a Multiplex Point-of-Care test for the combined detection of Human Immunodeficiency Virus (HIV), Hepatitis B and C and Syphilis) from serum, plasma samples collected prospectively or retrospectively in Ivory Coast and Kenya.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-09-11; most recent amendment 2026-01-30.
Trial Details
NCT Number NCT07170748
Lead Sponsor MagIA Diagnostics
Collaborators: Institut Pasteur, Kenya Medical Research Institute, Programme PAC-CI, Site ANRS-MIE de Côte d'Ivoire
Conditions Multiplex Testing of HIV, HBV, HCV and Syphilis, HIV, HBV, HCV, Syphilis, Point of Care Testing
Enrollment 2,950 participants
Start Date 2025-07-29
Primary Completion 2026-04 (estimated)
Study Completion 2026-04 (estimated)
Updated on ClinicalTrials.gov 2026-02-02